Context Therapeutics’ (CNTX) “Buy” Rating Reiterated at D. Boral Capital
Context Therapeutics (NASDAQ:CNTX – Get Free Report)‘s stock had its “buy” rating reissued by stock analysts at D. Boral Capital in a report issued on Friday,Benzinga reports. They presently have a $9.00 price target on the stock. A number of other research analysts also recently issued reports on the company. HC Wainwright reaffirmed a “buy” […]
Context Therapeutics (NASDAQ:CNTX – Get Free Report)‘s stock had its “buy” rating reissued by stock analysts at D. Boral Capital in a report issued on Friday,Benzinga reports. They presently have a $9.00 price target on the stock. A number of other research analysts also recently issued reports on the company. HC Wainwright reaffirmed a “buy” […]
